194 related articles for article (PubMed ID: 21318335)
1. Use of intravitreal triamcinolone and bevacizumab in Coats' disease with central macular edema.
Böhm MR; Uhlig CE
Graefes Arch Clin Exp Ophthalmol; 2011 Jul; 249(7):1099-101. PubMed ID: 21318335
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
3. Resolution of severe macular edema in adult coats' disease with intravitreal triamcinolone and bevacizumab injection.
Jun JH; Kim YC; Kim KS
Korean J Ophthalmol; 2008 Sep; 22(3):190-3. PubMed ID: 18784449
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
Sheth S; Rush R; Natarajan S; Gillies M
Clin Exp Ophthalmol; 2011; 39(7):673-81. PubMed ID: 22452685
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up.
Cervantes-Castañeda RA; Giuliari GP; Gallagher MJ; Yilmaz T; MacDonell RE; Quinones K; Foster CS
Eur J Ophthalmol; 2009; 19(4):622-9. PubMed ID: 19551679
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
7. Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema.
Liu Q; Hu Y; Yu H; Yuan L; Hu J; Atik A; Guan M; Li D; Li X; Tang S
Retina; 2015 Feb; 35(2):272-9. PubMed ID: 25105313
[TBL] [Abstract][Full Text] [Related]
8. Response of Retinal Sensitivity to Intravitreal Anti-angiogenic Bevacizumab and Triamcinolone Acetonide for Patients with Diabetic Macular Edema over One Year.
Mylonas G; Schranz M; Scholda C; Karst S; Reiter G; Baumann L; Schmidt-Erfurth U; Kriechbaum K
Curr Eye Res; 2020 Sep; 45(9):1107-1113. PubMed ID: 31961224
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion.
Wu WC; Cheng KC; Wu HJ
Eye (Lond); 2009 Dec; 23(12):2215-22. PubMed ID: 19218991
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).
Paccola L; Costa RA; Folgosa MS; Barbosa JC; Scott IU; Jorge R
Br J Ophthalmol; 2008 Jan; 92(1):76-80. PubMed ID: 17965109
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results.
Kriechbaum K; Prager S; Mylonas G; Scholda C; Rainer G; Funk M; Kundi M; Schmidt-Erfurth U;
Eye (Lond); 2014 Jan; 28(1):9-15; quiz 16. PubMed ID: 24336297
[TBL] [Abstract][Full Text] [Related]
12. The effect of intravitreal bevacizumab injection as the initial treatment for Coats' disease.
Zheng XX; Jiang YR
Graefes Arch Clin Exp Ophthalmol; 2014 Jan; 252(1):35-42. PubMed ID: 23873253
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial.
Ahmadieh H; Ramezani A; Shoeibi N; Bijanzadeh B; Tabatabaei A; Azarmina M; Soheilian M; Keshavarzi G; Mohebbi MR
Graefes Arch Clin Exp Ophthalmol; 2008 Apr; 246(4):483-9. PubMed ID: 17917738
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema.
Faghihi H; Roohipoor R; Mohammadi SF; Hojat-Jalali K; Mirshahi A; Lashay A; Piri N; Faghihi Sh
Eur J Ophthalmol; 2008; 18(6):941-8. PubMed ID: 18988166
[TBL] [Abstract][Full Text] [Related]
15. Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion.
Kim JY; Park SP
Korean J Ophthalmol; 2009 Dec; 23(4):259-65. PubMed ID: 20046685
[TBL] [Abstract][Full Text] [Related]
16. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
17. Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration.
Jonas JB; Libondi T; Golubkina L; Spandau UH; Schlichtenbrede F; Rensch F
Acta Ophthalmol; 2010 Sep; 88(6):630-4. PubMed ID: 19432871
[TBL] [Abstract][Full Text] [Related]
18. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
Shimura M; Nakazawa T; Yasuda K; Shiono T; Iida T; Sakamoto T; Nishida K
Am J Ophthalmol; 2008 May; 145(5):854-61. PubMed ID: 18328456
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion.
Cheng KC; Wu WC; Chen KJ
Eye (Lond); 2009 Nov; 23(11):2023-33. PubMed ID: 19798117
[TBL] [Abstract][Full Text] [Related]
20. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study.
Isaac DL; Abud MB; Frantz KA; Rassi AR; Avila M
Acta Ophthalmol; 2012 Feb; 90(1):56-60. PubMed ID: 20015098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
